Novartis’ Entresto Labeling Expansion Bid Heads To US FDA Panel

 
• By Sue Sutter
Small narrow living room with space problems and a sofa between walls (3D Rendering)
The Entresto trial in heart failure patients with preserved ejection fraction narrowly missed its primary endpoint. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers